Aura Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	84.79	59.52	31.69	41.06	121.58	149.06
Short-Term Investments	29.94	84.73	119.4	185.09	67.23	-
Cash & Short-Term Investments	114.73	144.24	151.09	226.15	188.81	149.06
Cash Growth	-10.36%	-4.54%	-33.19%	19.78%	26.66%	757.03%
Other Current Assets	3.77	5.5	9.53	5.64	7.89	4.64
Total Current Assets	118.5	149.74	160.62	231.79	196.7	153.7
Net Property, Plant & Equipment	17.89	18.45	20.59	22	26.04	6.2
Other Long-Term Assets	1.29	1.24	1.29	1.28	1.19	0.13
Total Assets	137.68	169.43	182.5	255.08	223.94	160.03
Accounts Payable	2.57	1.55	2.3	1.79	2.92	2.4
Accrued Expenses	10.87	13.59	9.46	7.88	4.57	4.34
Current Portion of Leases	3.27	3.24	3.15	2.69	2.96	0.62
Total Current Liabilities	16.71	18.38	14.91	12.36	10.46	7.36
Long-Term Leases	13.72	14.13	15.62	16.87	17.9	0.36
Total Long-Term Liabilities	13.72	14.13	15.62	16.87	17.9	0.36
Total Liabilities	30.43	32.52	30.53	29.23	28.35	7.72
Additional Paid-in Capital	621.56	617.43	525.93	512.62	406.56	304.45
Accumulated Other Comprehensive Income	-0.21	-0.1	0.26	0.54	-0.07	-
Retained Earnings	-514.1	-480.42	-374.23	-287.31	-210.9	-152.14
Total Common Shareholders' Equity	107.25	136.91	151.97	225.85	195.58	152.32
Shareholders' Equity	107.25	136.91	151.97	225.85	195.58	152.32
Total Liabilities & Equity	137.68	169.43	182.5	255.08	223.94	160.03
Total Debt	16.99	17.38	18.77	19.56	20.86	0.98
Net Cash (Debt)	97.74	126.86	132.33	206.59	167.95	148.09
Net Cash Growth	-22.96%	-4.13%	-35.95%	23.01%	13.41%	751.42%
Net Cash Per Share	1.51	2.10	2.67	5.21	5.61	28.70
Book Value	107.25	136.91	151.97	225.85	195.58	152.32
Book Value Per Share	1.66	2.27	3.06	5.70	6.53	29.52
Tangible Book Value	107.25	136.91	151.97	225.85	195.58	152.32
Tangible Book Value Per Share	1.66	2.27	3.06	5.70	6.53	29.52

SEC Filings: 10-K · 10-Q